Agenus (AGEN) executive Armen sold 82,107 shares for $534K at $6.50
Insider transactions reported
Garo H Armen (executive at Agenus Inc., AGEN) reported that they sold 82,107 shares for $534K at $6.50, and acquired 119,178 shares at $3.36 on Sep 13, 2021. After these transactions the filing shows 770,773 shares held directly.
- Reporting person
- Armen Garo H
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Sep 13, 2021 | Exercise or conversion of a derivative (M) | Common Stock1 | +119,178 | $3.36 | $400K | 852,880 direct |
| Sep 13, 2021 | Open-market sale (S) | Common Stock4 | -82,107 | $6.50 | $534K | 770,773 direct |
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Sep 13, 2021 | Exercise or conversion of a derivative (M) | Stock Option, right to buyOn 119,178 Common Stock | -119,178 | - | - | 0 direct |
Holdings before and after
- Common Stock: 733,702 to 770,773 direct
- Stock Option, right to buy: 119,178 to 0 direct
Other positions listed
- Common Stock: 125,969 indirect, See Footnote
- Common Stock: 579,000 indirect, See Footnote
Footnotes from the filing
- 1. The options subject to the transaction reported on this Form 4 would have expired on September 14, 2021.
- 2. Shares are held in Dr. Armen's IRA accounts.
- 3. Dr. Armen is trustee and has investment authority for the Garo Armen 2020 2 Year AG GRAT holder of 479,000 shares of our Common Stock. Dr. Armen is a general partner in Pixie Partners, a General Partnership ( Pixie ), which as of the date of this report owns 100,000 shares of our Common Stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Pixie and disclaims beneficial ownership to the extent of his pecuniary interest therein.
- 4. Represents sales of shares, as a consequence of the exercise of options, to cover Federal, state and local tax withholding requirements and the exercise price payment related to the option exercise. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.44 to $6.55. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction codes in this filing
- Open-market sale:
- Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
- Exercise or conversion of a derivative:
- Code M marks the exercise or conversion of an option or other derivative under an exempt plan.
FAQ
What did Armen report in this AGEN Form 4?
Garo H Armen (executive at Agenus Inc., AGEN) reported that they sold 82,107 shares for $534K at $6.50, and acquired 119,178 shares at $3.36 on Sep 13, 2021. After these transactions the filing shows 770,773 shares held directly.
How many AGEN shares does Armen hold after this filing?
The filing shows 770,773 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
Was this AGEN insider sale made under a 10b5-1 plan?
The filing's footnotes do not mention a Rule 10b5-1 trading plan.
What does transaction code S mean on an SEC Form 4?
Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
Historical context for AGEN
Earlier insider filings at AGEN
- Jul 2, 2021SEC Form 4: ARMEN GARO H was granted 2,679 units of Common Stock, increasing direct ownership by 0.37% to 733,702 units
- Jul 2, 2021SEC Form 4: Buell Jennifer was granted 10,597 units of Common Stock, increasing direct ownership by 9% to 127,091 units
- Jul 2, 2021SEC Form 4: Hirsch Susan B was granted 4,908 units of Common Stock, increasing direct ownership by 56% to 13,637 units
- Jul 2, 2021SEC Form 4 filed by Corvese Brian
- Jul 2, 2021SEC Form 4 filed by KLASKIN CHRISTINE M
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2000
Follow AGEN and get a push notification the moment its next story breaks.